Comparison of selected clinical and serological features of ssSSc subjects in the Canadian Scleroderma Research Group cohort compared to those in other large cohorts. Adapted from Marangoni, et al 5. Used with permission. All data are represented as n (%) unless specified otherwise.
| Canada, n = 27 | Pittsburgh 20002, n = 48 | Germany 20083, n = 22 | Spain 20114, n = 69 | Brazil 20135, n = 79 | |
|---|---|---|---|---|---|
| Total n of cohort | 1417 | 555 | 1483 | 916 | 947 |
| With ssSSc | 27 (2) | 48 (9) | 22 (1.5) | 69 (7.5) | 79 (8.3) |
| Age at disease onset, mean (SD) | 44.4 (14.6) | 51 (range 17–78) | — | 44.9 (18.2) | 46.04 (13.1) |
| Female | 24/27 (88.9) | 41/48 (85) | 20/22 (90.9) | 62/69 (89.8) | 76/79 (96.2) |
| Digital ulcers | 5/27 (18.5) | 16/48 (33) | 7/22 (31.8) | 10/69 (14.5) | 19/79 (24.1) |
| Articular disease | 3/27 (11.5) | 21/48 (44) | 7/22 (31.8) | 9/69 (13) | 35/79 (44.3) |
| Muscular disease | 1/27 (3.7) | 2/48 (4) | 3/22 (13.6) | 2/69 (2.9) | 10/79 (12.7) |
| Esophageal dysmotility | 14/25 (56.0) | 37/48 (77) | 16/22 (72.7) | 31/69 (44.9) | 64/77 (83.1) |
| Interstitial lung disease | 7/27 (25.9) | 32/47 (68) | 16/22 (72.7) | 44/69 (63.7) | 37/65 (56.9) |
| Pulmonary hypertension | 3/26 (11.5) | 11/48 (23) | 3/22 (13.6) | 17/69 (24.0) | 18/79 (22.8) |
| Anticentromere antibodies | 9/18 (50.0) | 15/45 (33) | 8/22 (36.4) | 27/69 (24.6) | 33/79 (41.8) |
| Mortality rate | 4/20 (20) | 19/48 (40) | — | 6/69 (8.7) | 6/79 (7.6) |
ssSSc: systemic sclerosis sine scleroderma.